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Sjögren's and plasma cell variant Castleman disease: a case report 
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SUMMARY 
Castleman disease is a rare cause of lymphoid hyperplasia and may result in localized symptoms or an aggressive, 
multisystem disorder. It can mimic other diseases like lymphoma or tuberculosis. It classically presents as a medias-
tinal mass that involves the lymphatic tissue primarily but can also affect extra lymphatic sites including the lungs, 
larynx, parotid glands, pancreas, meninges, and muscles. In HIV and HHV8-negative patients with idiopathic multi-
centric Castleman disease, pathogenesis may involve autoimmune mechanisms. We highlight and report a case of a 
34-year-old Ghanaian female who was successfully diagnosed and managed for Sjögren's as well as plasma cell var-
iant Castleman disease with combination chemotherapy and rituximab followed by eighteen months maintenance 
therapy with pulse chlorambucil and prednisolone and three monthly rituximab.  
 




Castleman disease (CD) is a polyclonal lymphoprolifer-
ative disorder also known as giant nodular hyperplasia 
or angiofollicular lymph node hyperplasia, angiomatous 
lymphoid hamartoma, lymph node hamartoma, and be-
nign giant lymphoma.1The first case report of CD was 
published in 1956 by Castleman et al and he later de-
scribed 13 patients with unicentric hyaline vascular CD 
of the chest.2 
 
CD is a rare disease and classically presents as a medi-
astinal mass that primarily involves the lymphatic tis-
sue3-5 but can affect extra lymphatic sites including the 
lungs, larynx, parotid glands, pancreas, meninges, and 
muscles.3-5  
 
Clinical presentation ranges from unicentric or localized 
lymph node involvement to a severe, multicentric, sys-
temic disorder which is associated with constitutional 
signs and symptoms such as fever, night sweats, easy 
fatigability and anaemia.6,7 
 
The underlying cause of CD remains unknown although 
both immunodeficiency and autoimmunity have been 
suggested. CD has been described in association with 
autoimmune and connective tissue diseases such as 
rheumatoid arthritis, myasthenia gravis, Evans’ syn-
drome, vitiligo, coeliac disease, Graves’ disease, ulcera-
tive colitis and immune thrombocytopenia8,6-11 and this 
may suggest a possible autoimmune pathology.12 How-
ever, it is not clear if autoimmunity is the underlying 
cause or result of CD. It has also been described with 
POEMS syndrome (polyneuropathy, organomegaly, 
endocrinopathy, M component, skin changes)13,14 Local-
ized disease can be cured by surgical resection of the 
affected lymph node while aggressive systemic therapy 
is required in Multicentric Castleman disease 
(MCD).15,16  
 
We present an obese 34 year old Ghanaian female with 
Sjögren's and plasma cell variant CD who presented 
with the classical signs of Sjögren's and was found to 
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She also had marked constitutional symptoms and was 
treated with six cycles of multiagent chemotherapy and 
rituximab (anti-CD-20 monoclonal antibody) followed 
by eighteen months maintenance therapy with monthly 
pulses of chlorambucil and prednisolone and three-
monthly rituximab.  
 
CASE REPORT 
A 34-year-old female was referred for a haematology 
consult on account of thrombocytosis following a diag-
nosis of Sjögren's disease at a private clinic. Patient had 
been unwell the preceding six months with a cold, dry 
mouth, excessive sweating but no history of weight loss.  
On examination, she was very severely obese with a 
BMI of 64.7 (weight 187kg, height 170 cm) not pale, 
afebrile, with swollen eyelids and enlarged submandibu-
lar lymph nodes.  Both lower limbs were swollen and 
tender with differential warmth. The liver and spleen 
were not enlarged. 
 
Laboratory tests done showed anaemia, elevated serum 
lactate dehydrogenase but liver function, renal function 
and uric acid levels were normal. Serum inflammatory 
markers, erythrocyte sedimentation rate and C-reactive 
protein, were elevated - 98 mm/hr and 20.6mg/dL, re-
spectively. HIV, Hepatitis B and C viral screening were 
negative. Serum HHV8 immunofluorescence assay was 
done and found to be negative. (Table 1) An abdomino-
pelvic ultrasound scan done to determine the presence 
of intra-abdominal lymphadenopathy was normal. 
 











Hb (gldl) 8.9 12.0 (11.0 – 16.0) 
MCV (fl) 71.3 85 (84 – 96) 
MCH (pg) 21.7 27.2 (26 – 32) 
WBC (x 109/l) 6.6 3.8 (2.5 – 8.5) 
Platelets (x 109/l) 381 211 (140 – 400) 
HIV 1 & 11 Negative   
C-reactive protein 
(mg/l) 
20.6 6.0 0.00-8.0 
 ESR mm/hr 98mm/hr 15 4-7 
LDH (U/L) 502  360 100-480  
Hepatitis B & C Negative   
Uric acid (Umol/L) 289 235 149-446 
 
An excisional biopsy of a submandibular lymph node 
was taken.  Histology showed lymphoid follicles with 
reactive germinal centers surrounded by concentric lay-
ers of small mature appearing lymphocytes.  
The interfollicular zones were expanded by a polymor-
phous mononuclear cell population with sheets of plas-
ma cells present, which were mature to immature in 
morphologic appearance.  A diagnosis of plasma cell 
variant of CD was made. Using the recently proposed 
consensus criteria,17 our patient had two major (charac-
teristic lymph node histopathology and multicentric 
lymphadenopathy), and three of 11 minor Criteria (ele-
vated C-reactive protein, anaemia, and constitutional 
symptoms). There was no histological evidence of ma-
lignant lymphoma. Immunohistochemistry is not rou-
tinely done in Ghana and was not requested.  
 
Patient was treated with 8 cycles of RCHOP (rituximab, 
cyclophosphamide, vincristine, doxorubicin and predni-
solone), given at 3 weekly intervals. With the com-
mencement of chemotherapy came rapid improvement 
in the patient’s clinical symptoms as well as resolution 
of peripheral lymphadenopathy. Maintenance therapy 
consisting of monthly pulses of chlorambucil and pred-
nisolone as well as three monthly courses of rituximab 
was given.  Patient had maintenance therapy for eight-
een months and was subsequently lost to follow-up. She 
presented again after five years with bilateral lacrimal, 
submandibular, cervical lymphadenopathy and constitu-
tional symptoms. A repeat lymph node biopsy revealed 
a relapse of CD. She was re-treated with RCHOP and 
went into a second clinical remission after six cycles of 
therapy with complete resolution of lymphadenopathy 
and constitutional symptoms. She is currently doing 
well on monthly pulses of chlorambucil.  
 
DISCUSSION 
This patient presented twice with some classical fea-
tures of CD such as the non-specific constitutional 
symptoms and lymphadenopathy as well as features of 
Sjögren's syndrome. The manifestations of CD are non-
specific and require histological diagnosis. Sjögren's 
syndrome is a systemic autoimmune disease that mainly 
affects the exocrine glands with lymphocytic infiltration 
of the glands particularly the salivary and lacrimal 
glands leading to the development of xerostomia (dry 
mouth) and keratoconjunctivitis sicca (dry eyes) with 
eventual damage or destruction of the glands18 Sjögren's 
syndrome primarily affects predominantly Caucasian 
perimenopausal women, with an incidence of 4–5 cases 
per 100 000.17 The syndrome can occur by itself (prima-
ry) or as secondary Sjögren’s syndrome when it is asso-
ciated with another connective tissue disease. In 
Sjögren's syndrome, a number of findings from litera-
ture have implicated the presence of a B-cell hyperactiv-
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Our patient had a previous underlying autoimmune dis-
order in the form of Sjögren's and this autoimmune re-
sponse may be the trigger of Castleman disease.19 The 
first reported case of MCD diagnosed in Ghana and 
successfully treated also had plasma cell variant and 
presented with two major and four minor criteria (con-
stitutional symptoms, anaemia, thrombocytopenia and 
elevated ESR).20 
 
The occurrence of B-cell non-Hodgkin lymphoma 
(NHL) represents the major complication in the evolu-
tion of Sjögren's syndrome.7,21 The risk of developing 
NHL, which is equivalent for both primary and second-
ary syndromes, is estimated to be over forty times great-
er than that observed in a comparable normal popula-
tion.21 NHL in patients with Sjögren's syndrome occur 
preferentially in salivary glands and in other mucosa-
associated lymphoid tissues (MALT) but also in lymph 
nodes and bone marrow. Persistent enlargement of pa-
rotid glands, adenopathy, monoclonal gammopathy, and 
cross-reactive idiotypes are all signs suggesting possible 
progression to lymphoma.22 The progression from be-
nign lymphocytic infiltration typical of Sjögren's syn-
drome to malignant NHL is undoubtedly a multistep 
process, but the causal molecular events are unknown. 
In the case presented, a biopsy done at time of relapse 
still showed CD. 
 
Some studies have implicated viruses like hepatitis B, 
Epstein Barr virus, and T lymphocytic viruses in the 
pathogenesis of Sjögren's syndrome and development of 
a cancer.23 Our patient was screened for hepatitis B, 
which was found to be negative. HHV8 is central to the 
pathogenesis of HIV-positive CD and occurs in 50% of 
those patients.24 Our patient was HIV and HHV8 nega-
tive and thus most likely had idiopathic CD which is 
usually associated with an autoimmune disease.  
Primary Sjögren's has also been described coexisting 
with CD in a few case reports and the Hyaline-vascular 
type of CD may be a lymphoproliferative disorder asso-
ciated with Sjögren's syndrome.25,26 This patient howev-
er had Plasma cell type CD. 
 
Unicentric Castleman disease (UCD), the less aggres-
sive form of the disorder, presents as a solitary lesion. It 
is usually seen in young and middle aged patients with-
out any sex predilection. The HV type is unicentric in 
90% of the cases.  
 
Histopathological findings in CD suggest an exaggerat-
ed response to antigenic stimuli seen in diseases associ-
ated with immune activation, such as rheumatoid arthri-
tis. Chronic inflammation resulting from exposure to an 
unknown antigen has been supported by the presence of 
excessive serum levels of interleukin6 (IL6), a cytokine 
with widespread effects on the immune system and 
haematopoiesis. Some believe it may play a central role 
in the pathophysiology of CD. The clinical features 
have been linked to IL6 serum levels, and surgical re-
moval of the involved lymph nodes or use of anti-IL6 
antibodies can slow down the symptoms.26,27 C-reactive 
protein which is a marker for IL6 was found to be very 




No curative agents for Sjögren’s syndrome exist. The 
treatment of the disorder is essentially symptomatic. 
Recent studies26,28 have analyzed new therapeutic ap-
proaches, focusing mainly on the use of biological 
agents. B-cell targeted therapies seem to be the most 
promising agents in primary Sjögren's syndrome, espe-
cially rituximab (anti-CD 20 monoclonal antibody), 
which has been used in reported cases. CD20 is consid-
ered a specific marker for B cells, highly expressed on 
the surface of pre-B lymphocytes and both residing and 
activated mature B cells, but not expressed in other 
cells.26 Malignant lymphoma in Sjögren's syndrome are 
typically a monoclonal B-cell neoplasm which may ex-
plain why rituximab should be considered a choice in 
their treatment.28 In some studies however, rituximab 
did not provide lasting benefit for patients with primary 
Sjögren's syndrome as it did not alleviate symptoms or 
disease activity at later end points. 29 
 
Successful treatment of MCD has been reported using 
rituximab30-32 in both HIV positive and negative pa-
tients, even when used as salvage therapy. It was first 
used for the treatment of HIV positive patients with 
MCD after chemotherapy-induced remission. Most 
MCD cases treated to date with rituximab have been 
HIV and HHV-8 positive patients.33-36 Rituximab was 
chosen in our patient as the first-line treatment since she 
also had a history of Sjögren's syndrome. 
 
The limitations of this report were the inability to get 
micrographs of the histology that was done on the 
lymph node biopsy and also immunophenotyping was 




Clinicians should be aware that Sjögren's can co-exisit 
with Castleman disease. Therefore, investigation of pa-
tients with suspected autoimmune disease and lymphad-
enopathy should include lymph node biopsy for histolo-
gy and immunohistochemistry where possible. Mono-
clonal antibodies such as rituximab can also be used in 
the treatment of both Sjögren's disease and CD in com-
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